开启核医疗“钥匙”，陈和生院士获广东科技奖突出贡献奖

Core Viewpoint - The successful clinical application of the first domestic Boron Neutron Capture Therapy (BNCT) device in Dongguan marks a significant advancement in nuclear medicine, driven by the efforts of Chen Hesheng and his team at the China Spallation Neutron Source [1][6] Group 1: Project Development and Achievements - The BNCT project, derived from the core technology of the China Spallation Neutron Source, has completed its first full-process treatment for a recurrent nasopharyngeal cancer patient [1] - The China Spallation Neutron Source is recognized as the first in China and the fourth in the world, serving as a "super microscope" for exploring the microscopic world [1][2] - The project has received significant funding, with over 1 billion yuan invested by Guangdong and Hong Kong to enhance its capabilities, increasing the number of experimental terminals from 3 to 11 [3][6] Group 2: Technical Innovations and Applications - BNCT utilizes nuclear reactions between neutrons and boron elements in tumors to destroy cancer cells, representing a targeted, dual approach to treatment [4][5] - The development of high-flux, miniaturized neutron sources through the China Spallation Neutron Source has addressed challenges associated with traditional nuclear reactors, making BNCT more accessible [5][6] - The RFQ-BNCT system, developed with independent intellectual property rights, integrates key technologies for precise positioning and controlled dosage, enhancing treatment efficiency [6] Group 3: Future Prospects and Expansion - The second phase of the China Spallation Neutron Source project has been approved, aiming to increase neutron spectrometers and experimental terminals, with completion expected by fall 2029 [7] - There is a vision to establish a cluster of large scientific devices in the Guangdong-Hong Kong-Macao Greater Bay Area, promoting deeper technological collaboration [7]